In conclusion, our data suggested that serum CXCL16 levels can be identified as a potential biomarker for the efficacy of chemotherapies, such as bevacizumab and other anti‐VEGF therapies for patients with advanced NSCLC. This evidence concerns the gene CXCL16 and non-small cell lung carcinoma.